A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis
- Conditions
- Atopic Dermatitis (AD)
- Interventions
- Drug: CGB-500 Ointment with 1% tofacitinib
- First Posted Date
- 2025-04-11
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- CAGE Bio Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT06923228
Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment with 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis
- Conditions
- Atopic Dermatitis (AD)
- Interventions
- Drug: CGB-500 with 0.5% tofacitinibDrug: CGB-500 Ointment with 1% tofacitinibDrug: Vehicle (placebo)
- First Posted Date
- 2025-02-05
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- CAGE Bio Inc.
- Target Recruit Count
- 180
- Registration Number
- NCT06810050
- Locations
- πΊπΈ
Center for Dermatology Clinical Research Inc., Fremont, California, United States
πΊπΈAblon Skin Institute and Research Center, Manhattan Beach, California, United States
πΊπΈTCR Medical Corporation, San Diego, California, United States
Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Interventions
- Other: placebo ointment
- First Posted Date
- 2022-08-04
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- CAGE Bio Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05487963
- Locations
- π¬πͺ
Kani Clinic, Tbilisi, Georgia
An Open-label Study Evaluating the Effectiveness of CGB-400 Topical Gel for Fungal Infection
- Conditions
- Fungal InfectionOnychomycosisTinea Unguium
- Interventions
- Drug: CGB-400 Topical Gel
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2022-04-07
- Lead Sponsor
- CAGE Bio Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT05202366
- Locations
- πΊπΈ
John Peter Smith Hospital, Fort Worth, Texas, United States
CGB-400 Topical Gel for the Treatment of Inflammatory Lesions of Rosacea
- First Posted Date
- 2021-05-14
- Last Posted Date
- 2022-08-09
- Lead Sponsor
- CAGE Bio Inc.
- Target Recruit Count
- 78
- Registration Number
- NCT04886739
- Locations
- πΊπΈ
Cage Bio Investigative Site 1, Fremont, California, United States
CGB-400 for the Reduction of Facial Redness
- First Posted Date
- 2020-08-11
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- CAGE Bio Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT04508660
- Locations
- πΊπΈ
Cage Bio Investigative Site 1, Fremont, California, United States
πΊπΈCage Bio Investigative Site 2, San Diego, California, United States
πΊπΈCage Bio Investigative Site 3, Edgewater, Florida, United States
CGB-400 for the Reduction of Facial Redness and Bumps and Blemishes
- First Posted Date
- 2020-08-11
- Last Posted Date
- 2020-08-12
- Lead Sponsor
- CAGE Bio Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT04508205
- Locations
- πΊπΈ
Cage Bio Investigative Site 3, Edgewater, Florida, United States
πΊπΈCage Bio Investigative Site 1, Fremont, California, United States
πΊπΈCage Bio Investigative Site 2, San Diego, California, United States
50 Human Subject Repeat Insult Patch Test
- Conditions
- ErythemaSensitisation
- Interventions
- Other: CB-0002B
- First Posted Date
- 2020-08-04
- Last Posted Date
- 2020-08-04
- Lead Sponsor
- CAGE Bio Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT04498676
- Locations
- πΊπΈ
AMA Laboratories Inc., New City, New York, United States
Clinical Evaluation of the Residual Antimicrobial Activity
- First Posted Date
- 2020-08-03
- Last Posted Date
- 2020-08-05
- Lead Sponsor
- CAGE Bio Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT04495920
- Locations
- πΊπΈ
Bioscience Laboratories, Inc., Bozeman, Montana, United States